Skip to main content
Clinical Trials/JPRN-UMIN000004826
JPRN-UMIN000004826CompletedPhase 2

Randomized crossover trial of Granisetron/Dexamethasone/Aprepitant versus Palonosetron/Dexamethasone/Aprepitant for the prevention of nausea and vomiting in patients receiving receiving Cisplatin containing chemotherapy for head and neck cancer - Randomized crossover trial of Granisetron/Dexamethasone/Aprepitant versus Palonosetron/Dexamethasone/Aprepitant for the prevention of nausea and vomiting in patients receiving receiving Cisplatin containing chemotherapy for head and neck cancer

Yokohama City University Graduate School of Medicine0 sites60 target enrollmentStarted: January 6, 2011Last updated:
Conditions

Trial Snapshot

Phase
Phase 2
Status
Completed
Sponsor
Enrollment
60

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
20years-old to 75years-old (—)
Sex
All

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • 1) with seizure disorder needing anticonvulsants unless clinically stable 2) with vomiting, retching, or grade 2 or higher nausea according to CTCAE 3) with QTc prolongation by electrocardiography (QTc: >470 msec) 4) with severe allergy to Palonosetron, Granisetron, Aprepitant and Dexamethasone 5) pregnant or nursing women or women who like be pregnant and men with partner willing to get pregnant 6) receiving an antiemetic drug 7) receiving pimozide (orap) 8) with history of mental disorder or treating it at the moment 9) doctor's decision not to be registered to this study

Investigators

Sponsor
Yokohama City University Graduate School of Medicine

Similar Trials